stoxline Quote Chart Rank Option Currency Glossary
  
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
0.624  -0.015 (-2.35%)    03-11 16:00
Open: 0.62
High: 0.6815
Volume: 143,993
  
Pre. Close: 0.639
Low: 0.6021
Market Cap: 6(M)
Technical analysis
2026-03-11 4:43:44 PM
Short term     
Mid term     
Targets 6-month :  0.79 1-year :  0.93
Resists First :  0.68 Second :  0.79
Pivot price 0.58
Supports First :  0.52 Second :  0.42
MAs MA(5) :  0.61 MA(20) :  0.56
MA(100) :  0.88 MA(250) :  1.28
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  71.7 D(3) :  68.2
RSI RSI(14): 52.3
52-week High :  2.2 Low :  0.42
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BFRG ] has closed below upper band by 25.1%. Bollinger Bands are 53.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.68 - 0.69 0.69 - 0.69
Low: 0.59 - 0.6 0.6 - 0.6
Close: 0.62 - 0.62 0.62 - 0.63
Company Description

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.

Headline News

Tue, 17 Feb 2026
BullFrog AI Faces Nasdaq Noncompliance, Delisting Risk Looms - TipRanks

Tue, 17 Feb 2026
BullFrog AI Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Wed, 31 Dec 2025
BullFrog AI Holdings issues stockholder letter, files exhibit with SEC - Investing.com India

Fri, 24 Oct 2025
BullFrog AI Holdings stockholders approve share issuance and reverse split - Investing.com

Fri, 25 Apr 2025
Bullfrog AI Announces Closing of $8.4 Million Initial Public Offering - ACCESS Newswire

Thu, 24 Apr 2025
BFRG Stock Price, News & Analysis - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Healthcare Information Services
Shares Out 0 (M)
Shares Float 11 (M)
Held by Insiders 8.97e+006 (%)
Held by Institutions 27.1 (%)
Shares Short 609 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.86e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 881.8 %
Return on Equity (ttm) -117.5 %
Qtrly Rev. Growth 116670 %
Gross Profit (p.s.) 0
Sales Per Share -328.86
EBITDA (p.s.) 30831
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 2.33
Stock Dividends
Dividend 0
Forward Dividend 586840
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android